Posts Tagged ‘Cáncer de mama’

Tuesday January 23rd, 2018

Researchers identify a protein that keeps metastatic breast cancer cells dormant

The time needed for breast cancer metastases (secondary lesions caused by cells that have escaped from the original tumour) to develop varies between patients, and little is known about the mechanisms that govern latency (the dormant state of cells that have already spread through the body). A study headed by ICREA researcher Roger Gomis at the Institute for Research in Biomedicine (IRB Barcelona) has identified the genes involved in the latent asymptomatic state of breast cancer metastases. The work sheds light on the molecular basis underlying how the expression of certain genes facilitates the spread of metastatic lesions. Dr. Aleix Prat, Head of the Clinical Oncology Department at Hospital Clínic and of the Translational genomics and targeted therapeutics in solid tumors research team at IDIBAPS, has participated in this study. Read the rest of this entry »

Comments Closed
Monday June 12th, 2017

Aleix Prat, named Board Member of the Breast International Group

Dr. Aleix Prat, Head of the Clinical Oncology Department at Hospital Clínic and of the Translational genomics and targeted therapeutics in solid tumors research team at IDIBAPS, has been named member of the Executive Board of the Breast International Group (BIG). The BIG is an international non-profit organisation that includes more than 56 cooperative groups from around the world, more than 10,000 experts and it is linked to more than 3,000 hospitals. Its main goal is to promote clinical and translational research in breast cancer. The appointment, which represents a recognition to his professional career in this field, took place during the annual meeting of the American Society of Clinical Oncology (ASCO) held in June 2-6 in Chicago. Read the rest of this entry »

Comments Closed
Wednesday November 30th, 2016

Hospital Clínic will implement a new genomic test to predict response to treatment in breast cancer

Researchers from Hospital Clínic and IDIBAPS lead an international study in which they have developed a genomic test to predict the response to chemotherapy in breast cancer. Hospital Clínic of Barcelona will be the first hospital in the world to implement this third generation test. This test is based on the data produced by the second-generation test PAM50, and for which Hospital Clínic is one of the reference centers. The article, published today in the journal Clinical Cancer Research, has been coordinated by Dr. Aleix Prat, Head of the Clinical Oncology Department at Hospital Clínic, the Translational genomics and targeted therapeutics in solid tumors research team at IDIBAPS and the Translational Genomics group of the Vall d’Hebron Institute of Oncology (VHIO). The study has involved several hospitals in Spain within the GEICAM breast cancer co-operative group, researchers from the University of North Carolina (USA), the Royal Marsden Foundation Trust in London, the University of Otago (New Zealand) and The University of Edinburgh (Scotland).

Read the rest of this entry »

Comments Closed
Thursday June 09th, 2016

First molecular test that enables fine-tuned prognosis and prediction in advanced breast cancer

Published today in JAMA Oncology, Principal Investigator of Vall d´Hebron Institute of Oncology´s (VHIO) Translational Genomics Group, and now  Team Leader of translational genomics and targeted therapeutics in solid tumors at the August Pi I Sunyer Biomedical Research Institute (IDIBAPS), and Head of Medical Oncology at the Hospital Clínic in Barcelona, Aleix Prat, has led a study showing the intrinsic subtyping of breast cancer by means of a genomic test as the most important prognostic factor in advanced or metastatic hormone-sensitive breast cancer. Findings show that the genomic classification of tumors — the molecular subtyping of primary tumors, can predict the evolution of patients from the onset of metastasis and that this cancer intrinsic classification can better guide treatment decisions in the first-line metastatic setting.  Read the rest of this entry »

Comments Closed

Categories

Posted in:

Monday June 17th, 2013

A population of cells which decreases after pregnancy is related to breast cancer risk

Epidemiological and experimental data suggest that full-term pregnancy (lasting 37 – 40 weeks) at an early age reduces the risk of developing breast cancer in postmenopausal women. However, the mechanism responsible for this protection is unknown. A study led by researchers at the Dana Farber Cancer Institute of the Harvard Medical School (Boston, USA), in collaboration with the Johns Hopkins University School of Medicine (Baltimore, USA), identifies molecular differences in breast cells from women with and without children. The work was published in the journal Cell Stem Cell from the Cell group, with Dr. Vanessa Almendro as its co-first author. Shes is a member of the IDIBAPS Molecular and Translational Oncology team directed by Dr. Pere Gascon, Chief of Oncology at the Hospital Clínic of Barcelona. The results of the investigation suggest that CD44+ p27+ cells are potential progenitors of estrogen receptor-positive (ER+) postmenopausal breast cancer, the most common form of the disease.

Read the rest of this entry »

Comments Closed